Latest Insider Transactions at Quanterix Corp (QTRX)
This section provides a real-time view of insider transactions for Quanterix Corp (QTRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Quanterix Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Quanterix Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
350,000
-15.42%
|
-
|
|
May 13
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.17%
|
$230,000
$46.38 P/Share
|
|
May 11
2021
|
Shawn Stetson Interim CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
1,423
+23.19%
|
-
|
|
May 03
2021
|
Amol Chaubal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
178
-0.15%
|
$10,324
$58.95 P/Share
|
|
May 03
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
217
-0.16%
|
$12,586
$58.95 P/Share
|
|
May 03
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
234
-0.18%
|
$13,572
$58.95 P/Share
|
|
May 03
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
147
-0.15%
|
$8,526
$58.95 P/Share
|
|
May 03
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,789
-0.07%
|
$341,551
$59.17 P/Share
|
|
Apr 27
2021
|
Laurie J Olson |
BUY
Grant, award, or other acquisition
|
Direct |
4,540
+50.0%
|
-
|
|
Apr 20
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.26%
|
$290,000
$58.26 P/Share
|
|
Apr 15
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-4.35%
|
$103,354
$62.14 P/Share
|
|
Apr 08
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.25%
|
$325,000
$65.38 P/Share
|
|
Apr 01
2021
|
Amol Chaubal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
165
-0.18%
|
$10,230
$62.66 P/Share
|
|
Apr 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
201
-0.19%
|
$12,462
$62.66 P/Share
|
|
Apr 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,432
-0.12%
|
$212,784
$62.66 P/Share
|
|
Apr 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
136
-0.18%
|
$8,432
$62.66 P/Share
|
|
Apr 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
215
-0.21%
|
$13,330
$62.66 P/Share
|
|
Apr 01
2021
|
Keith Crandell |
BUY
Grant, award, or other acquisition
|
Direct |
211
+1.42%
|
$12,871
$61.45 P/Share
|
|
Apr 01
2021
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
193
+1.66%
|
$11,773
$61.45 P/Share
|
|
Apr 01
2021
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
294
+1.96%
|
$17,934
$61.45 P/Share
|
|
Apr 01
2021
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
223
+1.63%
|
$13,603
$61.45 P/Share
|
|
Mar 19
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-4.17%
|
$96,686
$58.36 P/Share
|
|
Mar 16
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.25%
|
$300,000
$60.96 P/Share
|
|
Mar 08
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.13%
|
$330,000
$66.46 P/Share
|
|
Mar 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
137
-0.28%
|
$11,097
$81.55 P/Share
|
|
Mar 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
202
-0.29%
|
$16,362
$81.55 P/Share
|
|
Mar 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,443
-0.17%
|
$278,883
$81.55 P/Share
|
|
Mar 01
2021
|
Amol Chaubal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
166
-0.27%
|
$13,446
$81.55 P/Share
|
|
Mar 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
217
-0.32%
|
$17,577
$81.55 P/Share
|
|
Feb 19
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
871
-0.64%
|
$77,519
$89.96 P/Share
|
|
Feb 19
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
871
-0.62%
|
$77,519
$89.96 P/Share
|
|
Feb 19
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
670
-0.67%
|
$59,630
$89.96 P/Share
|
|
Feb 19
2021
|
Amol Chaubal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
733
-0.59%
|
$65,237
$89.96 P/Share
|
|
Feb 19
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,493
-0.09%
|
$310,877
$89.96 P/Share
|
|
Feb 18
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.25%
|
$420,000
$84.49 P/Share
|
|
Feb 11
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-4.01%
|
$131,693
$79.62 P/Share
|
|
Feb 09
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.16%
|
$385,000
$77.95 P/Share
|
|
Feb 08
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
3,679
+9.63%
|
-
|
|
Feb 08
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
BUY
Grant, award, or other acquisition
|
Direct |
3,373
+11.84%
|
-
|
|
Feb 08
2021
|
John J Fry General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
3,679
+9.41%
|
-
|
|
Feb 08
2021
|
Amol Chaubal Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,789
+15.67%
|
-
|
|
Feb 08
2021
|
William Geist Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,906
+9.84%
|
-
|
|
Feb 08
2021
|
David C. Duffy SVP R&D and CTO |
BUY
Grant, award, or other acquisition
|
Direct |
2,146
+4.9%
|
-
|
|
Feb 08
2021
|
E Kevin Hrusovsky Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
18,397
+1.78%
|
-
|
|
Feb 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
105
-0.24%
|
$7,140
$68.21 P/Share
|
|
Feb 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
163
-0.26%
|
$11,084
$68.21 P/Share
|
|
Feb 01
2021
|
Amol Chaubal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
133
-0.26%
|
$9,044
$68.21 P/Share
|
|
Feb 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
8,249
-0.16%
|
$544,434
$66.71 P/Share
|
|
Feb 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
182
-0.29%
|
$12,376
$68.21 P/Share
|
|
Jan 25
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.25%
|
$385,000
$77.92 P/Share
|